Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study (2023)
Attributed to:
MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2665-9913(23)00091-7
Publication URI: http://dx.doi.org/10.1016/s2665-9913(23)00091-7
Type: Journal Article/Review
Parent Publication: The Lancet Rheumatology
Issue: 5